Core Viewpoint - Regenerative medicine provider, Lijing Medical Group, has announced a strategic partnership with Boustead APEX, Boustead and Company, and cornerstone investor Raffles Capital to facilitate its listing in the U.S., marking a significant step in its global expansion and positioning in the international capital market [1][3]. Company Summary - Lijing Medical Group specializes in stem cell regenerative therapies and has established a strong reputation and extensive medical network across Asia, leveraging years of research and clinical application [3][8]. - The upcoming U.S. listing is expected to provide substantial capital infusion, an international governance framework, and support from top global investors, enhancing the company's growth potential [3][5]. Industry Summary - The global regenerative medicine market is experiencing exponential growth due to an aging population and the rising prevalence of chronic and degenerative diseases, creating a significant demand for advanced regenerative therapies [5]. - The partnership with Boustead APEX and Boustead and Company aims to enhance Lijing's research capabilities, expand clinical applications, and deepen collaborations with leading international research institutions and healthcare systems [5][6].